NeurogesX
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(650) 358-3300Website
www.neurogesx.comRevenue
$17.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NeurogesX
NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain. The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas PhRead more
NeurogesX Org Chart
NJ
Drug Safety Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeurogesX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NeurogesX is spiking on competitors!
Earning: See what the market has to say on NeurogesX recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
NeurogesX, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once NeurogesX has new funding data
Click to see if NeurogesX had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NeurogesX
Check if NeurogesX has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NeurogesX launches new products
Recommended Actions
Find VP level buyers at NeurogesX
Find 3 more new buyers
Compare Similar Companies to NeurogesX
Compare insights from companies similar to NeurogesX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NeurogesX
$17.1M
11-50
Private
$44M
1998
MG
Mark GiovanettiSenior Director Technical Accounting and Secretary Reporting
Company Profile Activity
Activity Insights
NeurogesX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeurogesX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeurogesX.
NeurogesX financials insights
Gather financial insights about NeurogesX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$44M
NeurogesX News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeurogesX
Sign Up For FreeTo access detailed company insights
NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX... Read More
